ADCs
ADCs
Structurally Informed Liability Analysis
Structurally Informed Liability Analysis
Identification of chemical liability sites (deamidation, oxidation, and isomerization), aggregation-prone patches, and problematic surface charges (positive, negative, and charge dipoles).
Identification of chemical liability sites (deamidation, oxidation, and isomerization), aggregation-prone patches, and problematic surface charges (positive, negative, and charge dipoles).
Payload Attachment Analysis
Payload Attachment Analysis
Quantitative analysis of ADC properties with different numbers of attached payloads (e.g. DAR) or different payload attachment sites, which exist in the drug product simultaneously.
Quantitative analysis of ADC properties with different numbers of attached payloads (e.g. DAR) or different payload attachment sites, which exist in the drug product simultaneously.
Payload Property Analysis
Payload Property Analysis
Surface properties of payloads and/or linkers (without attached protein) are analysed as if they were small molecule drugs.
For quantitative analysis, the properties of a payload of interest are either compared to our internal database of ADC payloads (shown), or our larger database of parenterally administered small molecule drugs.
Surface properties of payloads and/or linkers (without attached protein) are analysed as if they were small molecule drugs.
For quantitative analysis, the properties of a payload of interest are either compared to our internal database of ADC payloads (shown), or our larger database of parenterally administered small molecule drugs.
Quantitative Surface Property Analysis
Quantitative Surface Property Analysis
Over 90 structure- and sequence-derived properties are compared to our internal database. Our database contains the properties of over 900 therapeutic monoclonal antibodies (mAbs) that are already marketed or in clinical trials.
This analysis can be used to compare different linkers or payloads.
Over 90 structure- and sequence-derived properties are compared to our internal database. Our database contains the properties of over 900 therapeutic monoclonal antibodies (mAbs) that are already marketed or in clinical trials.
This analysis can be used to compare different linkers or payloads.
Expert Analysis
Expert Analysis
Data from liabilities, surface properties, and AI predictions are evaluated by our experienced scientists, in the context of the desired target product profile. Their deep expertise in formulation development ensures optimal interpretation of results and formulation strategy design.
Structurally Informed Liability AnalysisIdentification of chemical liability sites (deamidation, oxidation, and isomerization), aggregation-prone patches, and problematic surface charges (positive, negative, and charge dipoles).
Interested in how this can work for your molecule?
